An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT02850029
• Date of registration: 27/07/2016
• Prospective Registration: No
• Primary sponsor: Centre Hospitalier Universitaire de Nimes
• Public title: An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey
• Scientific title: An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey
• Date of first enrolment: May 21, 2016
• Target sample size: 964
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02850029
• Study type: Observational

Countries of recruitment

Australia, Chile, France, Greece, United Kingdom

Contacts

• Name: Claire Roger, MD
• Affiliation: Centre Hospitalier Universitaire de Nîmes

Key inclusion & exclusion criteria

Inclusion Criteria:

- Age = 18 years old

- Intensive care unit patients

- Receiving aminoglycoside therapy for a sepsis according to the Third International
Consensus Definitions for Sepsis and Septic Shock

Exclusion Criteria:

- Aged < 18 years of age

- Previous inclusion in the study



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Critical Illness

Underdosing of Aminoglycosides

Intervention(s)

Other: Observational study, no intervention

Primary Outcome(s)

Aminoglycoside current practices descriptive data in intensive care units [Time Frame: Seven first days of aminoglycoside therapy]

Secondary Outcome(s)

Aminoglycoside therapy duration [Time Frame: Seven first days of aminoglycoside therapy]

Aminoglycoside therapeutic drug monitoring [Time Frame: Seven first days of aminoglycoside therapy]

Aminoglycoside dosing regimens [Time Frame: Seven first days of aminoglycoside therapy]

Secondary ID(s)

IRB 15 04 08

Source(s) of Monetary Support

Please refer to primary and secondary sponsors